Login / Signup

Characterization of antibodies to SARS-CoV-2 in lyophilized plasma prepared with amotosalen-UVA pathogen reduction.

Christophe MartinaudAnil BagriCheng-Ting TsaiRafael R de AssisMichelle GatmaitanPeter V RobinsonDavid SeftelSaahir KhanPhilip L FelgnerLaurence M Corash
Published in: Transfusion (2023)
The antibody activity in pooled pathogen-reduced lyophilized CCPs demonstrated minimal impact due to pathogen reduction treatment and lyophilization.
Keyphrases
  • sars cov
  • candida albicans
  • respiratory syndrome coronavirus
  • clinical trial
  • phase iii